Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial
Abstract The incidence of nonalcoholic fatty liver disease (NAFLD) has recently increased and is related to obesity and the associated surge in type 2 diabetes mellitus (T2DM) and metabolic syndromes. This trial follows up on our previous work and forms part of the ToPiND study. We aimed to combine...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Health/LWW
2022-09-01
|
| Series: | Hepatology Communications |
| Online Access: | https://doi.org/10.1002/hep4.1993 |